Sleep Duration and Risk of Type 2 Diabetes: A Meta-analysis of Prospective Studies

Shan, Zhilei; Ma, Haile; Xie, Manling; Yan, Peipei; Guo, Yanjun; Bao, Wei; Rong, Yuluo; Jackson, Chandra L.; Hu, Frank B.; Liu, Liegang

doi:10.2337/dc14-2073

Cited by 680 publications

(535 citation statements)

References 54 publications

(80 reference statements)

Supporting

Mentioning

479

Contrasting

Unclassified

Order By: Relevance

“…Our metaanalysis takes the evidence further by including 18 studies and analyzing the association of different categories of short sleep (,5, 5-6, and 6-7 h) duration as well as long sleep (8-9 and .9 h) with MetS. In fact, results of our metaregression sensitivity analysis show that exclusion of the data for greater than 9 hours of sleep duration from the rest of the different durations of sleep (,5, 5-6, 6-7, 8-9), predicts a dose-dependent response, a finding not shown in prior metaanalyses (19,20,46). In other words, every 1 hour decrease in sleep duration corresponds to a 0.06 increase in the OR of having MetS.…”

Section: Systematic Reviewsupporting

confidence: 55%

Sleep Duration and Metabolic Syndrome. An Updated Dose–Risk Metaanalysis

et al. 2015

View full text Add to dashboard Cite

Rationale: Several studies have reported that both short and long sleep durations are associated with the metabolic syndrome, but whether a dose-response relationship exists is unclear.Objectives: We performed a metaanalysis to study the magnitude of the association between the different durations of sleep and metabolic syndrome. Methods:We searched in the databases of PubMed, Web of Science, and Ovid (all Journals@Ovid) from inception to October 4, 2014 for cross-sectional studies where an association between metabolic syndrome and sleep duration was analyzed. Measurements and Main Results:Eighteen studies with 75,657 participants were included. Daily sleep duration of 7 to 8 hours was used as the reference group. The odds ratio (OR) of having metabolic syndrome for short (,7 h) sleep was 1.23 (95% CI, 1.11-1.37; P , 0.001; I 2 , 71%). The ORs for less than 5 hours, 5 to 6 hours, and 6 to 7 hours of sleep were 1.51 (95% CI, 1.10-2.08; P = 0.01), 1.28 (95% CI, 1.11-1.48; P , 0.001), and 1.16 (95% CI, 1.02-1.31; P = 0.02), respectively. The coefficient of sleep duration on log of ORs was 20.06 6 0.02 (P = 0.02). The OR for long sleep duration was 1.13 (95% CI, 0.97-1.32; P = 0.10; I 2 , 89%).Conclusions: A dose-response relationship exists between short sleep duration and metabolic syndrome. Those who report a sleep duration of less than 5 hours have a 1.5 higher odds of having metabolic syndrome. Our study does not support the notion that long sleep is associated with metabolic syndrome.

show abstract

Section: Systematic Reviewsupporting

confidence: 55%

Sleep Duration and Metabolic Syndrome. An Updated Dose–Risk Metaanalysis

et al. 2015

View full text Add to dashboard Cite

show abstract

“…A Finnish study in overweight individuals with impaired glucose tolerance found an increased risk of T2DM only in participants with long sleep duration ⩾9 h (hazard ratio (HR) 2·29, 95 % CI 1·38, 3·80) (14) . Finally, two recent meta-analyses of nine (17) and fourteen (18) prospective cohort studies have also confirmed the U-shaped relationship (Fig. 1).…”

Section: Association Between Sleep Duration and The Risk Of Type 2 DIsupporting

confidence: 54%

The role of sleep duration in diabetes and glucose control

Alnaji

Law

2016

Proc. Nutr. Soc.

View full text Add to dashboard Cite

Sleep curtailment is common in the Westernised world and coincides with an increase in the prevalence of type 2 diabetes mellitus (T2DM). This review considers the recently published evidence for whether sleep duration is involved in the development of T2DM in human subjects and whether sleep has a role to play in glucose control in people who have diabetes. Data from large, prospective studies indicate a U-shaped relationship between sleep duration and the development of T2DM. Smaller, cross-sectional studies also support a relationship between short sleep duration and the development of both insulin resistance and T2DM. Intervention studies show that sleep restriction leads to insulin resistance, with recent sleep extension studies offering tantalising data showing a potential benefit of sleep extension on glucose control and insulin sensitivity. In people with established diabetes the published literature shows an association between poor glucose control and both short and long sleep durations. However, there are currently no studies that determine the causal direction of this relationship, nor whether sleep interventions are likely to offer benefit for people with diabetes to help them achieve tighter glucose control

show abstract

“…Meta-analyses support a U-shaped association between sleep duration and incident type 2 diabetes [8,9]. Furthermore, sleep duration predicts cardiovascular outcomes [10], and both short [11][12][13][14] and long [14,15] sleep time is associated with incident CHD in prospective studies.…”

Section: Introductionmentioning

confidence: 92%

Incident diabetes mellitus may explain the association between sleep duration and incident coronary heart disease

Svensson

Kitliński

et al. 2017

Diabetologia

View full text Add to dashboard Cite

Aims/hypothesis Sleep duration is a risk factor for incident diabetes mellitus and CHD. The primary aim of the present study was to investigate, in sex-specific analyses, the role of incident diabetes as the possible biological mechanism for the reported association between short/long sleep duration and incident CHD. Considering that diabetes is a major risk factor for CHD, we hypothesised that any association with sleep duration would not hold for cases of incident CHD occurring before incident diabetes ('non-diabetes CHD') but would hold true for cases of incident CHD following incident diabetes ('diabetes-CHD'). Methods A total of 6966 men and 9378 women aged 45-73 years from the Malmö Diet Cancer Study, a populationbased, prospective cohort, who had answered questions on habitual sleep duration and did not have a history of prevalent diabetes or CHD were included in the analyses. Incident cases of diabetes and CHD were identified using national registers. Sex-specific Cox proportional hazards regression models were stratified by BMI and adjusted for known covariates of diabetes and CHD. Results Mean follow-up times for incident diabetes (n = 1137/ 1016 [men/women]), incident CHD (n = 1170/578), nondiabetes CHD (n = 1016/501) and diabetes-CHD (n = 154/ 77) were 14.2-15.2 years for men, and 15.8-16.5 years for women. In men, short sleep duration (< 6 h) was associated with incident diabetes (HR 1.35, 95% CI 1.01, 1.80), CHD (HR 1.41, 95% CI 1.06, 1.89) and diabetes-CHD (HR 2.34, 95% CI 1.20, 4.55). Short sleep duration was not associated with incident non-diabetes CHD (HR 1.35, 95% CI 0.98, 1.87). Long sleep duration (≥ 9 h) was associated with incident diabetes (HR 1.37, 95% CI 1.03, 1.83), CHD (HR 1.33, 95% CI 1.01, 1.75) and diabetes-CHD (HR 2.10, 95% CI 1.11, 4.00). Long sleep duration was not associated with incident non-diabetes CHD (HR 1.33, 95% CI 0.98, 1.80). In women, short sleep duration was associated with incident diabetes (HR 1.53, 95% CI 1.16, 2.01), CHD (HR 1.46, 95% CI 1.03, 2.07) and diabetes-CHD (HR 2.88, 95% CI 1.37, 6.08).Akiko Kishi Svensson and Thomas Svensson contributed equally to this study. Electronic supplementary materialThe online version of this article (https://doi.org/10.1007/s00125-017-4464-3) contains peer-reviewed but unedited supplementary material, which is available to authorised users.

show abstract

Sleep Duration and Risk of Type 2 Diabetes: A Meta-analysis of Prospective Studies

Cited by 680 publications

References 54 publications

Sleep Duration and Metabolic Syndrome. An Updated Dose–Risk Metaanalysis

Sleep Duration and Metabolic Syndrome. An Updated Dose–Risk Metaanalysis

The role of sleep duration in diabetes and glucose control

Incident diabetes mellitus may explain the association between sleep duration and incident coronary heart disease

Contact Info

Product

Resources

About